These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 1516761)
1. Repetitive in vivo treatment with human recombinant interleukin-1 beta modifies beta-cell function in normal rats. Wogensen LD; Reimers J; Nerup J; Kolb-Bachofen V; Kröncke KD; Almdal T; Mandrup-Poulsen T Diabetologia; 1992 Apr; 35(4):331-9. PubMed ID: 1516761 [TBL] [Abstract][Full Text] [Related]
2. Strain-dependent differences in sensitivity of rat beta-cells to interleukin 1 beta in vitro and in vivo: association with islet nitric oxide synthesis. Reimers JI; Andersen HU; Mauricio D; Pociot F; Karlsen AE; Petersen JS; Mandrup-Poulsen T; Nerup J Diabetes; 1996 Jun; 45(6):771-8. PubMed ID: 8635652 [TBL] [Abstract][Full Text] [Related]
3. Intra-peritoneal administration of interleukin-1 beta induces impaired insulin release from the perfused rat pancreas. Wogensen L; Helqvist S; Pociot F; Johannesen J; Reimers J; Mandrup-Poulsen T; Nerup J Autoimmunity; 1990; 7(1):1-12. PubMed ID: 2103305 [TBL] [Abstract][Full Text] [Related]
4. Functional and morphological effects of interleukin-1 beta on the perfused rat pancreas. Wogensen LD; Kolb-Bachofen V; Christensen P; Dinarello CA; Mandrup-Poulsen T; Martin S; Nerup J Diabetologia; 1990 Jan; 33(1):15-23. PubMed ID: 2406177 [TBL] [Abstract][Full Text] [Related]
5. Repetitive exposure of pancreatic islets to interleukin-1 beta. An in vitro model of pre-diabetes? Helqvist S; Zumsteg UW; Spinas GA; Palmer JP; Mandrup-Poulsen T; Egeberg J; Nerup J Autoimmunity; 1991; 10(4):311-8. PubMed ID: 1772965 [TBL] [Abstract][Full Text] [Related]
6. Interleukin 1 beta induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. Reimers JI; Bjerre U; Mandrup-Poulsen T; Nerup J Cytokine; 1994 Sep; 6(5):512-20. PubMed ID: 7530059 [TBL] [Abstract][Full Text] [Related]
7. Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells. Studies in rodent and human islets and in normal rats. Zumsteg U; Reimers JI; Pociot F; Mørch L; Helqvist S; Brendel M; Alejandro R; Mandrup-Poulsen T; Dinarello CA; Nerup J Diabetologia; 1993 Aug; 36(8):759-66. PubMed ID: 8405744 [TBL] [Abstract][Full Text] [Related]
8. Studies on the mechanisms causing inhibition of insulin secretion in rat pancreatic islets exposed to human interleukin-1 beta indicate a perturbation in the mitochondrial function. Sandler S; Bendtzen K; Borg LA; Eizirik DL; Strandell E; Welsh N Endocrinology; 1989 Mar; 124(3):1492-501. PubMed ID: 2521822 [TBL] [Abstract][Full Text] [Related]
9. Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on beta-cells in vivo or ex vivo. Christensen UB; Mauricio D; Reimers JI; Andersen HU; Kalland T; Nerup J; Mandrup-Poulsen T Autoimmunity; 1996; 23(4):257-68. PubMed ID: 8915032 [TBL] [Abstract][Full Text] [Related]
11. The frog skin host-defense peptide CPF-SE1 improves glucose tolerance, insulin sensitivity and islet function and decreases plasma lipids in high-fat fed mice. Srinivasan D; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YHA Eur J Pharmacol; 2015 Oct; 764():38-47. PubMed ID: 26123844 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 inhibits glucose-modulated insulin and glucagon secretion in rat islet monolayer cultures. Rabinovitch A; Pukel C; Baquerizo H Endocrinology; 1988 Jun; 122(6):2393-8. PubMed ID: 2453340 [TBL] [Abstract][Full Text] [Related]
13. Glucose intolerance in thyrotoxic rats: role of insulin, glucagon, and epinephrine. Ikeda T; Mokuda O; Tominaga M; Mashiba H Am J Physiol; 1988 Dec; 255(6 Pt 1):E843-9. PubMed ID: 3059820 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 beta inhibition of insulin release in rat pancreatic islets: possible involvement of G-proteins in the signal transduction pathway. Rabuazzo AM; Buscema M; Caltabiano V; Anello M; Degano C; Patanè G; Vigneri R; Purrello F Diabetologia; 1995 Jul; 38(7):779-84. PubMed ID: 7556978 [TBL] [Abstract][Full Text] [Related]
15. In vivo administration of interleukin-1 inhibits glucose-stimulated insulin release. Wang Y; Goodman M; Lumerman J; Sussman KE; Dahl R; Lafferty KJ; Draznin B Diabetes Res Clin Pract; 1989 Sep; 7(3):205-11. PubMed ID: 2691218 [TBL] [Abstract][Full Text] [Related]
16. Metabolic and endocrine effects of interleukin-1 in obese, diabetic Zucker fa/fa rats. del Rey A; Monge-Arditi G; Klusman I; Besedovsky HO Exp Clin Endocrinol Diabetes; 1996; 104(4):317-26. PubMed ID: 8886749 [TBL] [Abstract][Full Text] [Related]
17. [The effect of oral synthetic protease inhibitor (FOY 305) on endocrine pancreas and carbohydrate and lipid metabolism in normal and streptozotocin-induced diabetic rats]. Eto M; Watanabe K; Kagaya T; Sakai Y; Yoshida S; Oyama K; Futaki G; Saito T; Takebe T; Ishii K Nihon Naibunpi Gakkai Zasshi; 1984 May; 60(5):684-95. PubMed ID: 6386547 [TBL] [Abstract][Full Text] [Related]
18. Different effects of glucose and glyburide on insulin secretion in rat pancreatic islets pre-exposed to interleukin-1 beta. Possible involvement of K+ and Ca2+ channels. Buscema M; Rabuazzo AM; Vinci C; Caltabiano V; Vigneri R; Purrello F Diabetologia; 1993 Sep; 36(9):791-6. PubMed ID: 8405748 [TBL] [Abstract][Full Text] [Related]
19. Not all insulin secretagogues sensitize pancreatic islets to recombinant human interleukin 1 beta. Johannesen J; Helqvist S; Nerup J Acta Endocrinol (Copenh); 1990 Oct; 123(4):445-52. PubMed ID: 1700570 [TBL] [Abstract][Full Text] [Related]
20. [In vitro and in vivo effect of gold thioglucose on the insulin- and glucagon-secretion of the isolated perfused rat pancreas]. Blech W; Bierwolf B; Weiss I; Ziegler M Biomed Biochim Acta; 1986; 45(4):507-22. PubMed ID: 3085662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]